Cheon Jinwoo is a South Korean chemist and nanomedicine researcher. He is the H. G. Underwood Professor of Chemistry at Yonsei University, the founding director of the Center for Nanomedicine at the Institute for Basic Science (IBS), and the director of the Max PlanckâÂÂYonsei IBS Center for Nanomedicine Deep Tissue Control (MPYIC).
Cheon is recognized for his contributions to inorganic materials chemistry and nanomedicine. His research focuses on developing chemical principles for the synthesis of inorganic nanoparticles and nanoprobes, and on their application to imaging, sensing, and controlling cellular functions in deep tissues of living systems.
Cheon is a fellow of the American Chemical Society, the Royal Society of Chemistry, and the Korean Academy of Science and Technology. He serves as an associate editor of the Journal of the American Chemical Society(JACS) and previously served as a senior editor of Accounts of Chemical Research(ACR). He is also a member of the editorial advisory boards of several leading scientific journals, including C&EN.
Throughout his career, he has received numerous awards, including the Inchon Award, the POSCO TJ Park Prize, and the Ho-Am Prize in Science. He has also been named a Clarivate Analytics Highly Cited Researcher and received the Glenn T. Seaborg Memorial Lectureship in Chemistry.
Cheon began his academic studies in chemistry at Yonsei University in 1981, where he earned his Bachelor of Science and Master of Science degrees in 1985 and 1987, respectively. He received his Ph.D. in chemistry in 1993 from the University of Illinois at UrbanaâÂÂChampaign under the supervision of Professor Gregory S. Girolami.
After completing his doctoral studies, Cheon conducted postdoctoral research at the UC Berkeley, and worked as a research associate at the UCLA. He later returned to South Korea, where he joined the KAIST, serving as an assistant and then associate professor.
In 2002, he joined Yonsei University as a faculty member and later became the H. G. Underwood Professor of Chemistry. From 2010 to 2016, he served as the director of the National Creative Research Initiative Center for Evolutionary Nanoparticles. In 2015, he became the founding director of the IBS Center for Nanomedicine at Yonsei University. In 2025, he co-founded AsiaâÂÂs second Max Planck Center, the Max PlanckâÂÂYonsei IBS Center for Nanomedicine Deep Tissue Control, serving as co-director alongside Professor Joachim Spatz of the Max Planck Institute for Medical Research.
CheonâÂÂs research has contributed to the development of nanomaterial-based biomedical technologies, including highly sensitive magnetic resonance imaging (MRI) contrast agents and nanoscale toolkits for cellular manipulation. In 2004, he experimentally demonstrated size-dependent MRI contrast effects using nanoparticles, which led to the development of magnetism-engineered iron oxide nanoparticles as ultra-sensitive MRI contrast agents with potential applications in early cancer detection.
He has also developed magnetic nanomachines composed of mechanically functional components at the submicrometer scale, enabling remote and precise control of nanostructures using external magnetic fields. These systems have been explored for applications such as targeted drug delivery and minimally invasive therapeutic approaches.
Since 2021, CheonâÂÂs work has significantly advanced the field of magnetogenetics, particularly for wireless control of deep tissue and brain activity in vivo. Magnetogenetics employs magnetic nanoparticles to generate mechanical forces or torque that activate mechanosensitive ion channels, such as Piezo1, enabling non-invasive and long-distance modulation of neuronal circuits. This approach offers new tools for studying brain function and has potential implications for the treatment of neurological disorders.